HilleVax (NASDAQ:HLVX) Stock Price Down 5.3%

HilleVax, Inc. (NASDAQ:HLVX)’s stock price dropped 5.3% on Tuesday . The stock traded as low as $13.09 and last traded at $13.17. Approximately 23,761 shares were traded during trading, a decline of 81% from the average daily volume of 122,535 shares. The stock had previously closed at $13.91.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of HilleVax in a report on Thursday, March 21st.

HilleVax Price Performance

The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62. The company’s fifty day simple moving average is $16.15 and its two-hundred day simple moving average is $14.63. The stock has a market capitalization of $589.68 million, a PE ratio of -4.12 and a beta of 0.65.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.02. As a group, sell-side analysts predict that HilleVax, Inc. will post -3.22 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Life Sciences X. L.P. Frazier bought 8,850 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were acquired at an average cost of $14.50 per share, with a total value of $128,325.00. Following the completion of the transaction, the insider now owns 8,544,187 shares of the company’s stock, valued at $123,890,711.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other HilleVax news, Director Aditya Kohli sold 8,866 shares of HilleVax stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $132,369.38. Following the transaction, the director now directly owns 812,878 shares of the company’s stock, valued at $12,136,268.54. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of HilleVax stock in a transaction on Thursday, April 4th. The shares were acquired at an average cost of $14.50 per share, for a total transaction of $128,325.00. Following the completion of the transaction, the insider now owns 8,544,187 shares of the company’s stock, valued at $123,890,711.50. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 78,039 shares of company stock valued at $986,464,242. Insiders own 29.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. acquired a new position in HilleVax during the first quarter valued at approximately $26,000. Federated Hermes Inc. lifted its position in shares of HilleVax by 80.6% during the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares in the last quarter. UBS Group AG lifted its position in shares of HilleVax by 9,300.0% during the fourth quarter. UBS Group AG now owns 1,692 shares of the company’s stock worth $28,000 after purchasing an additional 1,674 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of HilleVax by 80.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company’s stock worth $30,000 after purchasing an additional 781 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of HilleVax by 57.4% during the first quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock worth $43,000 after purchasing an additional 943 shares in the last quarter. 86.42% of the stock is owned by institutional investors and hedge funds.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.